XNAS · Healthcare · Biotechnology
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.30 | -0.26 | +13.33% | $0 | ✅ Beat | +3.49% | +6.18% | — |
| 2026-04-30 | Q1 2026 | -0.30 | -0.14 | +53.33% | $0 | ✅ Beat | -11.65% | +3.08% | +4.72% |
| 2026-03-13 |
| Q4 2025 |
| -0.37 |
| -0.27 |
| +27.03% |
| $0 |
| ✅ Beat |
| -15.00% |
| +0.16% |
| -12.56% |
| 2025-11-07 | Q3 2025 | -0.42 | -0.36 | +14.29% | $15.0M | ✅ Beat | — | — | — |
| 2025-03-20 | Q4 2024 | -0.46 | -0.51 | -10.87% | $0 | ❌ Miss | -1.98% | +3.96% | -29.70% |
| 2024-05-13 | Q1 2024 | -0.54 | -0.40 | +25.93% | $0 | ✅ Beat | -1.07% | +2.30% | -18.98% |
| 2024-03-20 | Q4 2023 | -0.50 | -0.45 | +10.00% | $0 | ✅ Beat | — | — | — |
| 2023-08-10 | Q2 2023 | -0.55 | -0.62 | -12.73% | $334,000 | ❌ Miss | — | — | — |
Showing last 8 quarters.